Life Science Nation Newsletter  | May 4,  2017  |  Issue 212

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Consulting
Life Science Investor Mandates (Apr. 27  - May 3)
Invests in Novel Cancer Drugs
Raises New Fund for Therapeutic and Medtech Opportunities
Bets Big on Late-Stage Therapeutic and Genomic Platforms
Invests in Medical Technology for Blood and Liver Diseases
In This Issue
Nature BioEntrepreneur Features LSN: Aligning Needs
LSN Services
Click to see investors that are a fit for your product and stage of development

Click here if you are a service provider and want to see a list of funded life science companies that are a fit for you

Click here if you want to receive free, targeted early stage dealflow for your life science investment firm

Free Copy of LSN's Book

LSN Videos
By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series, LSN

Life Science Nation (LSN) has created a funding and partnering platform for early-stage life science companies in biotech, medtech, diagnostics and digital health that is unique to the industry. The platform consists of two databases, one tracks emerging life science companies and the other curates investors from around the world who are funding these entities. Augmenting these two platforms is the Redefining Early Stage Investments (RESI) Conference series and an I-Bank, Boston Innovation Capital (BIC) that help facilitate the matching up of buyers and sellers.

LSN's unique position and range of capabilities has attracted interest from both domestic and foreign life science entities looking to leverage LSN's global access to technology, specifically the plethora of technology assets in North America. This has resulted in various projects that utilize LSN's infrastructure and reach into its partnering network. As a result LSN decided to offer a Sourcing and Ranking Service (SRS) that allows pharma and other buyer/licensees a way to quickly develop a complete picture of and gain access to the assets targeting a particular indication or specific technology type...

By Shaoyu Chang, MD, MPH, Director of Research & Asia Business Development Liaison, LSN

The year 2016 saw strong outbound investments from Asia, with China leading the pack. However, the investment landscape is rapidly changing, influenced by regulatory pressure, political uncertainty, and market demand. For North American entrepreneurs seeking opportunities in Asia, it is critical to understand your counterpart's strategy and incentives. Therefore for RESI San Diego, LSN has introduced new panel sessions to the Asia-North America Track in order to highlight the current key players in the region.

China Healthcare Investors

China is clearly a frontrunner in outbound activities. China's foreign direct investment (FDI) set a record of US$94.2 billion in 2016, up 189% in North America and 90% in Europe, compared to the prior year. Despite the strict currency restrictions implemented by the Chinese government by the end of 2016, this trend is generally expected to continue in the long run...
By Michael Quigley, VP of Market Research, LSN

Fundraising for diagnostics companies, like most early stage healthcare technologies, is no easy task. A relative lack of a thriving M&A/IPO exit environment compared to other life science sectors along with high profile flops in the space has made some investors wary. However there exists a significant need for advancement in the field of diagnostics. From pharma companies wanting novel biomarkers to more accurately stratify patients for clinical trials, to the rise of personalized therapies via genomic testing, there's a growing need for more accurate diagnostics and in many disease areas they do not currently exist.

In this session, we will hear from 5 Investors including VCs, large corporations and angels with experience and intent to invest in early stage diagnostics companies. The speakers will cover the types of investments they are looking to make and share insights they have learned working within the space. For any entrepreneur looking to raise capital for a diagnostic technology this is a must attend panel. Look below to see the speakers for yourself. We hope to see you in San Diego.
  • Nola Masterson (Managing Director, Science Futures)
  • Denis Bronnikov (Global Licensing Director, Roche Diagnostics)
  • Tom Hawes (Managing Director, Sandbox Industries)
  • Terry Moore (Managing Partner, Moore Venture Partners)
  • Alexis Ji (Partner, Illumina Ventures)